Join to View Full Profile
333 Cedar StreetP.O. Box 208042New Haven, CT 06520
Phone+1 203-200-5180
Fax+1 203-200-5170
Dr. Saperstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Nuclear Radiology, 2000 - 2001- New York Presbyterian Hospital (Columbia Campus)Residency, Radiology-Diagnostic, 1996 - 2000
Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 1993 - 1995
Duke University School of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 1994 - Present
CT State Medical License 2007 - 2026
FL State Medical License 2006 - 2017
NY State Medical License 1999 - 2013
NJ State Medical License 2001 - 2009
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Publications & Presentations
PubMed
- 1 citationsLong-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer.Natalia Kunst, Jessica B Long, Sarah Westvold, Preston C Sprenkle, Isaac Y Kim
JAMA Network Open. 2024-10-01 - 5 citationsPET Image Denoising using a Deep-Learning Method for Extremely Obese Patients.Hui Liu, Hamed Yousefi, Niloufar Mirian, MingDe Lin, David Menard
IEEE Transactions on Radiation and Plasma Medical Sciences. 2022-09-01 - Clinical PET/CT utilization during the COVID-19 pandemic: initial experience at Yale UniversityMehmet Emin Adin, Haruka Uezono, Edvin Isufi, Yulei Pang, William Zucconi
Nuclear Medicine Communications. 2021-11-01
Press Mentions
Radiologists Bring New Molecular Imaging Technology to YaleJanuary 19th, 2021
Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First PatientDecember 12th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
